𝔖 Bobbio Scriptorium
✦   LIBER   ✦

FCGR2AandFCGR3Apolymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

✍ Scribed by Kjersem, Janne B; Skovlund, Eva; Ikdahl, Tone; Guren, Tormod; Kersten, Christian; Dalsgaard, Astrid M; Yilmaz, Mette K; Fokstuen, Tone; Tveit, Kjell M; Kure, Elin H

Book ID
125398971
Publisher
BioMed Central
Year
2014
Tongue
English
Weight
384 KB
Volume
14
Category
Article
ISSN
1471-2407

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Fluorouracil, Leucovorin, and Oxaliplati
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
✍ Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Br πŸ“‚ Article πŸ“… 2009 πŸ› American Society of Clinical Oncology 🌐 English βš– 201 KB

## Purpose This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation sta